Journal article
No association between BMI and immunotoxicity or clinical outcomes for immune checkpoint inhibitors
Abstract
Background: The impact of BMI on immune checkpoint inhibitor toxicity and efficacy has not been clearly characterized. Methods: The authors conducted a retrospective single-center study of patients with advanced unresectable/metastatic cancer initiated on immune checkpoint inhibitors. Results: Of the 409 patients included in the study, 115 (28%) had a BMI ≥30. There was no difference in the development of immune-related adverse events, …
Authors
Yeung C; Kartolo A; Holstead R; Moffat GT; Hanna L; Hopman W; Baetz T
Journal
Immunotherapy, Vol. 14, No. 10, pp. 765–776
Publisher
Taylor & Francis
Publication Date
July 2022
DOI
10.2217/imt-2021-0250
ISSN
1750-743X